Details of the Drug Combinations

General Information of This Drug (ID: DMH07Y3)

Drug Name
Letrozole   DMH07Y3
Synonyms
Femara; Femera; Letoval; Letrozol; Novartis Brand of Letrozole; CGS 20267; CGS-20267; FEM-345; Femara (TN); Letrozole [USAN:INN]; CGS 20267, Femara, Piroxicam, Letrozole; Letrozole (JAN/USP/INN); 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
Indication
Disease Entry ICD 11 Status REF
Estrogen-receptor positive breast cancer N.A. Approved [1]
Hormonally-responsive breast cancer 2C60-2C65 Approved [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

431 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABIRATERONE + Letrozole DCFI89C ABIRATERONE Clear cell renal cell carcinoma (Cell Line: A498) [3]
ABIRATERONE + Letrozole DC6A079 ABIRATERONE Glioma (Cell Line: SF-268) [3]
ABIRATERONE + Letrozole DC1RVPR ABIRATERONE Renal cell carcinoma (Cell Line: SN12C) [3]
ABIRATERONE + Letrozole DCAU6LG ABIRATERONE Invasive ductal carcinoma (Cell Line: HS 578T) [4]
ABIRATERONE + Letrozole DC1JVNU ABIRATERONE Invasive ductal carcinoma (Cell Line: BT-549) [4]
ABIRATERONE + Letrozole DCNR2OI ABIRATERONE Adenocarcinoma (Cell Line: NCIH23) [5]
ABIRATERONE + Letrozole DC4ONZ7 ABIRATERONE Amelanotic melanoma (Cell Line: M14) [5]
ABIRATERONE + Letrozole DCIB9WA ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
ABIRATERONE + Letrozole DC34FMB ABIRATERONE Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Anastrozole + Letrozole DCSUWIH Anastrozole Adenocarcinoma (Cell Line: DU-145) [3]
Anastrozole + Letrozole DCN6OLV Anastrozole Adenocarcinoma (Cell Line: HT29) [3]
Anastrozole + Letrozole DCK9491 Anastrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Anastrozole + Letrozole DCAO6FX Anastrozole Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Anastrozole + Letrozole DCV1MQP Anastrozole Amelanotic melanoma (Cell Line: M14) [3]
Anastrozole + Letrozole DCZ9WON Anastrozole Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Anastrozole + Letrozole DC2V2BW Anastrozole Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Anastrozole + Letrozole DCK7FD5 Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Anastrozole + Letrozole DCRGZHK Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Anastrozole + Letrozole DCUQYJ8 Anastrozole Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Anastrozole + Letrozole DCHQC2J Anastrozole Lung adenocarcinoma (Cell Line: EKVX) [3]
Anastrozole + Letrozole DC4F8EM Anastrozole Malignant melanoma (Cell Line: UACC62) [3]
Anastrozole + Letrozole DCME2NV Anastrozole Melanoma (Cell Line: UACC-257) [3]
Anastrozole + Letrozole DC3DAKQ Anastrozole Melanoma (Cell Line: MALME-3M) [3]
Anastrozole + Letrozole DC2VUPN Anastrozole Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Anastrozole + Letrozole DCKG4AI Anastrozole Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Anastrozole + Letrozole DCTM0KX Anastrozole Prostate carcinoma (Cell Line: PC-3) [3]
Anastrozole + Letrozole DCSAWVU Anastrozole Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Anastrozole + Letrozole DCRQ8KL Anastrozole Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Anastrozole + Letrozole DC8XM9G Anastrozole Invasive ductal carcinoma (Cell Line: BT-549) [4]
Arfolitixorin + Letrozole DC73MHN Arfolitixorin Adenocarcinoma (Cell Line: HCT116) [5]
Crizotinib + Letrozole DC1DFGF Crizotinib Adenocarcinoma (Cell Line: DU-145) [3]
Crizotinib + Letrozole DC368IF Crizotinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Crizotinib + Letrozole DCM5SZN Crizotinib Amelanotic melanoma (Cell Line: M14) [3]
Crizotinib + Letrozole DCKDVGI Crizotinib Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Crizotinib + Letrozole DCQ04HM Crizotinib Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Crizotinib + Letrozole DC8WTCI Crizotinib Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Crizotinib + Letrozole DCK25MM Crizotinib Melanoma (Cell Line: UACC-257) [3]
Crizotinib + Letrozole DCQXS1U Crizotinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Crizotinib + Letrozole DCC91IW Crizotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Crizotinib + Letrozole DCA2TEP Crizotinib Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Crizotinib + Letrozole DCXI7U0 Crizotinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Crizotinib + Letrozole DCPLZTF Crizotinib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Crizotinib + Letrozole DCOUO00 Crizotinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Crizotinib + Letrozole DC6ETZH Crizotinib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Dacarbazine + Letrozole DCSXRG4 Dacarbazine Adenocarcinoma (Cell Line: SW-620) [3]
Dacarbazine + Letrozole DC8Q7XJ Dacarbazine Adenocarcinoma (Cell Line: HCT116) [3]
Dacarbazine + Letrozole DC9ATT2 Dacarbazine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Dacarbazine + Letrozole DCIPRA1 Dacarbazine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Dacarbazine + Letrozole DC3J5P4 Dacarbazine Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Dacarbazine + Letrozole DC9SUZU Dacarbazine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Dacarbazine + Letrozole DCK1QDY Dacarbazine Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Dexrazoxane + Letrozole DCBQ881 Dexrazoxane Colon adenocarcinoma (Cell Line: COLO 205) [4]
Epirubicin + Letrozole DCTRRTW Epirubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Epirubicin + Letrozole DCXHEYT Epirubicin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Epirubicin + Letrozole DCGWXTI Epirubicin Astrocytoma (Cell Line: SNB-19) [3]
Epirubicin + Letrozole DCVMN6Z Epirubicin Clear cell renal cell carcinoma (Cell Line: A498) [3]
Epirubicin + Letrozole DC44MPA Epirubicin Glioma (Cell Line: SF-268) [3]
Epirubicin + Letrozole DCVXTNE Epirubicin Renal cell carcinoma (Cell Line: SN12C) [3]
Epirubicin + Letrozole DCPYJ3T Epirubicin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Epirubicin + Letrozole DC6U98C Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Epirubicin + Letrozole DCQDL57 Epirubicin Amelanotic melanoma (Cell Line: M14) [5]
Epirubicin + Letrozole DC6X7KU Epirubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Epirubicin + Letrozole DCDHQCI Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Epirubicin + Letrozole DCKH9C1 Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Epirubicin + Letrozole DC1XUKC Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Epirubicin + Letrozole DCUWSXO Epirubicin Melanoma (Cell Line: UACC-257) [5]
Epirubicin + Letrozole DCWT86F Epirubicin Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Epirubicin + Letrozole DCT3PPQ Epirubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Epirubicin + Letrozole DC9YIGW Epirubicin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Gefitinib + Letrozole DCTOG6H Gefitinib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Letrozole DCON3LT Gefitinib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Indazole derivative 5 + Letrozole DCBVMI1 Indazole derivative 5 Colon adenocarcinoma (Cell Line: COLO 205) [4]
Indazole derivative 5 + Letrozole DCA5D92 Indazole derivative 5 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Indazole derivative 5 + Letrozole DCGHF9E Indazole derivative 5 Invasive ductal carcinoma (Cell Line: BT-549) [4]
Indazole derivative 5 + Letrozole DCP3KFD Indazole derivative 5 Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Indazole derivative 5 + Letrozole DC4TFZV Indazole derivative 5 Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Indazole derivative 5 + Letrozole DC9RXDP Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Indazole derivative 5 + Letrozole DC1KVTG Indazole derivative 5 Lung adenocarcinoma (Cell Line: HOP-62) [5]
Indazole derivative 5 + Letrozole DCM8JXE Indazole derivative 5 Melanoma (Cell Line: MALME-3M) [5]
Indazole derivative 5 + Letrozole DCB2K6O Indazole derivative 5 Melanoma (Cell Line: UACC-257) [5]
JNK-IN-8 + Letrozole DCVIHU6 JNK-IN-8 Glioma (Cell Line: SF-295) [3]
Lenalidomide + Letrozole DCL5LBF Lenalidomide Adenocarcinoma (Cell Line: HCT116) [5]
Lenalidomide + Letrozole DCKGHX7 Lenalidomide Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Letrozole + Pentostatin DCHQW7C Pentostatin Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Letrozole + Pentostatin DCFXWJW Pentostatin Lung adenocarcinoma (Cell Line: EKVX) [3]
Letrozole + Pentostatin DC98DAA Pentostatin Melanoma (Cell Line: UACC-257) [3]
Letrozole + Pentostatin DC5THDD Pentostatin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Letrozole + Pentostatin DCURN9D Pentostatin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Letrozole + Fulvestrant DCSODBJ Fulvestrant Adenocarcinoma (Cell Line: HCC-2998) [3]
Letrozole + Fulvestrant DCX45KO Fulvestrant Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Letrozole + Fulvestrant DC9G1DO Fulvestrant High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Letrozole + Ruxolitinib DC8P1EX Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [3]
Letrozole + Hepzato DCHUMAA Hepzato Adenocarcinoma (Cell Line: DU-145) [3]
Letrozole + Hepzato DCI4ZPZ Hepzato Adenocarcinoma (Cell Line: HT29) [3]
Letrozole + Hepzato DCCHMRE Hepzato Glioma (Cell Line: SF-295) [3]
Letrozole + Ixabepilone DC48QDY Ixabepilone Melanoma (Cell Line: SK-MEL-2) [3]
Letrozole + Dactinomycin DC6XKAE Dactinomycin Adenocarcinoma (Cell Line: OVCAR3) [3]
Letrozole + Dactinomycin DC4J0LC Dactinomycin Adenocarcinoma (Cell Line: HT29) [3]
Letrozole + Dactinomycin DCSA3DM Dactinomycin Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Letrozole + Dactinomycin DCKFCWO Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Letrozole + Dactinomycin DCN3KLS Dactinomycin Lung adenocarcinoma (Cell Line: EKVX) [3]
Letrozole + Dactinomycin DCICLK3 Dactinomycin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Letrozole + DFN-15 DC4TGP1 DFN-15 Adenocarcinoma (Cell Line: NCIH23) [3]
Letrozole + DFN-15 DCCZOF0 DFN-15 Anaplastic large cell lymphoma (Cell Line: SR) [3]
Letrozole + DFN-15 DCMEGAB DFN-15 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Letrozole + DFN-15 DCL46FT DFN-15 Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Letrozole + Cyclophosphamide DCXQ4IH Cyclophosphamide Glioblastoma (Cell Line: SNB-75) [3]
Letrozole + Cyclophosphamide DCPIVBH Cyclophosphamide Glioma (Cell Line: SF-268) [3]
Letrozole + Cyclophosphamide DCT63MH Cyclophosphamide Malignant melanoma (Cell Line: UACC62) [3]
Letrozole + Cyclophosphamide DCNF142 Cyclophosphamide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Letrozole + LIAROZOLE DCWX2AR LIAROZOLE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Letrozole + LIAROZOLE DCS0JRC LIAROZOLE Clear cell renal cell carcinoma (Cell Line: A498) [3]
Letrozole + LIAROZOLE DCMQURF LIAROZOLE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Letrozole + LIAROZOLE DCQT1Y4 LIAROZOLE Lung adenocarcinoma (Cell Line: HOP-62) [3]
Letrozole + LIAROZOLE DCEFSWK LIAROZOLE Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Letrozole + Methotrexate DCG64OD Methotrexate Adenocarcinoma (Cell Line: HCT-15) [3]
Letrozole + Methotrexate DC540QX Methotrexate Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Letrozole + Methotrexate DCN3LF8 Methotrexate Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Letrozole + Methotrexate DCLXS2C Methotrexate Amelanotic melanoma (Cell Line: M14) [3]
Letrozole + Methotrexate DCBAUZU Methotrexate Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Letrozole + Methotrexate DCIE6AG Methotrexate Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Letrozole + Methotrexate DC25JQI Methotrexate Glioma (Cell Line: SF-539) [3]
Letrozole + Methotrexate DC545NE Methotrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Letrozole + Methotrexate DC0YDVK Methotrexate Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Letrozole + Methotrexate DC4SZCJ Methotrexate Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Letrozole + Methotrexate DCBCY2Q Methotrexate Malignant melanoma (Cell Line: UACC62) [3]
Letrozole + Methotrexate DCL4918 Methotrexate Melanoma (Cell Line: UACC-257) [3]
Letrozole + Isoniazid DCOH5JU Isoniazid Adenocarcinoma (Cell Line: HT29) [3]
Letrozole + Isoniazid DCKNISM Isoniazid Astrocytoma (Cell Line: U251) [3]
Letrozole + Isoniazid DCLGNS9 Isoniazid Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Letrozole + Isoniazid DC767YJ Isoniazid Glioma (Cell Line: SF-295) [3]
Letrozole + Isoniazid DC1H20R Isoniazid Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Letrozole + Plicamycin DCM5O8O Plicamycin Adenocarcinoma (Cell Line: A549) [3]
Letrozole + Plicamycin DCFW913 Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Letrozole + Plicamycin DC0YJQ3 Plicamycin Malignant melanoma (Cell Line: UACC62) [3]
Letrozole + Plicamycin DCX0XXE Plicamycin Melanoma (Cell Line: MALME-3M) [3]
Letrozole + Plicamycin DC1N2RZ Plicamycin Melanoma (Cell Line: SK-MEL-2) [3]
Letrozole + Nilotinib DCP5TTH Nilotinib Adenocarcinoma (Cell Line: HT29) [3]
Letrozole + Nilotinib DCQGXQY Nilotinib Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Letrozole + Nilotinib DCKZTTG Nilotinib Amelanotic melanoma (Cell Line: M14) [3]
Letrozole + Nilotinib DCG7T73 Nilotinib Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Letrozole + Nilotinib DC61CHF Nilotinib Lung adenocarcinoma (Cell Line: HOP-62) [3]
Letrozole + Triapine DCAUN1H Triapine Adenocarcinoma (Cell Line: DU-145) [3]
Letrozole + Triapine DC14VA4 Triapine Adenocarcinoma (Cell Line: HCT116) [3]
Letrozole + Triapine DC4W88J Triapine Astrocytoma (Cell Line: U251) [3]
Letrozole + Triapine DCOYDMO Triapine Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Letrozole + Triapine DCJH0HP Triapine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Letrozole + Triapine DCXZTNU Triapine Lung adenocarcinoma (Cell Line: EKVX) [3]
Letrozole + Triapine DCHMW55 Triapine Melanoma (Cell Line: MALME-3M) [3]
Letrozole + Triapine DC4VSDM Triapine Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Letrozole + Topetecan DCYTHE6 Topetecan Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Letrozole + Pralatrexate DC8QUXT Pralatrexate Chronic myelogenous leukemia (Cell Line: K-562) [3]
Letrozole + Pralatrexate DC44ANT Pralatrexate Glioblastoma (Cell Line: SNB-75) [3]
Letrozole + Pralatrexate DCVJEX1 Pralatrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Letrozole + Terameprocol DC5WIRD Terameprocol Adenocarcinoma (Cell Line: HCT-15) [3]
Letrozole + Terameprocol DCEF62E Terameprocol Adenocarcinoma (Cell Line: HCC-2998) [3]
Letrozole + Terameprocol DC3VAUR Terameprocol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Letrozole + Terameprocol DCACT2Y Terameprocol Lung adenocarcinoma (Cell Line: EKVX) [3]
Letrozole + Ifosfamide DC4IC79 Ifosfamide Adenocarcinoma (Cell Line: NCIH23) [3]
Letrozole + Ifosfamide DCR1JC7 Ifosfamide Adenocarcinoma (Cell Line: SW-620) [3]
Letrozole + Ifosfamide DCSIZSO Ifosfamide Adenocarcinoma (Cell Line: HCT116) [3]
Letrozole + Ifosfamide DC7ONVS Ifosfamide Chronic myelogenous leukemia (Cell Line: K-562) [3]
Letrozole + Ifosfamide DC754VJ Ifosfamide Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Letrozole + Ifosfamide DCGM5X2 Ifosfamide Lung adenocarcinoma (Cell Line: EKVX) [3]
Letrozole + Ifosfamide DC5E5N0 Ifosfamide Prostate carcinoma (Cell Line: PC-3) [3]
Letrozole + Docetaxel DCUEYC8 Docetaxel Lung adenocarcinoma (Cell Line: EKVX) [3]
Letrozole + Raloxifene DCAKM5U Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Letrozole + Raloxifene DC16P0C Raloxifene Amelanotic melanoma (Cell Line: M14) [3]
Letrozole + Raloxifene DC5BRSA Raloxifene Glioma (Cell Line: SF-295) [3]
Letrozole + Raloxifene DC9M7WK Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Letrozole + Raloxifene DCSSMWC Raloxifene Malignant melanoma (Cell Line: UACC62) [3]
Letrozole + Bendamustine hydrochloride DCEN74V Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCT-15) [3]
Letrozole + Bendamustine hydrochloride DC36CTJ Bendamustine hydrochloride Malignant melanoma (Cell Line: UACC62) [3]
Letrozole + Bendamustine hydrochloride DC2D5K9 Bendamustine hydrochloride Melanoma (Cell Line: SK-MEL-2) [3]
Letrozole + Bendamustine hydrochloride DC22L67 Bendamustine hydrochloride Melanoma (Cell Line: UACC-257) [3]
Letrozole + Bendamustine hydrochloride DC1BE6T Bendamustine hydrochloride Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Letrozole + Bendamustine hydrochloride DCRBETP Bendamustine hydrochloride Renal cell carcinoma (Cell Line: SN12C) [3]
Letrozole + Sirolimus DC4MYEK Sirolimus Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Letrozole + Sirolimus DCNBP7W Sirolimus High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Letrozole + Sirolimus DC4DE81 Sirolimus Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Letrozole + Mitomycin DC9SZT1 Mitomycin Adenocarcinoma (Cell Line: HCC-2998) [3]
Letrozole + Mitomycin DCM0Y0R Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Letrozole + Mitomycin DCKAK9A Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Letrozole + Mitomycin DC5TA9C Mitomycin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Letrozole + SY-1425 DCGR1K3 SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Letrozole + SY-1425 DC8HJPP SY-1425 Lung adenocarcinoma (Cell Line: HOP-62) [3]
Letrozole + SY-1425 DC58R1U SY-1425 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Letrozole + Vincristine DCCKQ6E Vincristine Lung adenocarcinoma (Cell Line: HOP-62) [3]
Letrozole + Altretamine DC4HC0B Altretamine Adenocarcinoma (Cell Line: DU-145) [3]
Letrozole + Altretamine DC4J3Z4 Altretamine Adenocarcinoma (Cell Line: NCIH23) [3]
Letrozole + Altretamine DC7T721 Altretamine Glioblastoma (Cell Line: SNB-75) [3]
Letrozole + Altretamine DC2KLHK Altretamine Malignant melanoma (Cell Line: UACC62) [3]
Letrozole + TEM DCZTV44 TEM Astrocytoma (Cell Line: U251) [3]
Letrozole + TEM DC08XET TEM Prostate carcinoma (Cell Line: PC-3) [3]
Letrozole + Idarubicin DC6JIXU Idarubicin Glioblastoma? (Cell Line: T98G) [3]
Letrozole + Idarubicin DC081KB Idarubicin Glioma (Cell Line: SF-539) [3]
Letrozole + Idarubicin DCDT96O Idarubicin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Letrozole + Idarubicin DC3RO0Z Idarubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Letrozole + Imatinib DCDFO44 Imatinib Amelanotic melanoma (Cell Line: M14) [3]
Letrozole + Imatinib DCNXSOS Imatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Letrozole + Imatinib DCWMG7I Imatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Letrozole + Imatinib DCMY3T0 Imatinib Lung adenocarcinoma (Cell Line: HOP-62) [3]
Letrozole + Imatinib DCDI7BT Imatinib Melanoma (Cell Line: UACC-257) [3]
Letrozole + Imatinib DCVMW1A Imatinib Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Letrozole + Bleomycin DCN2ZVM Bleomycin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Letrozole + Valrubicin DC9V811 Valrubicin Adenocarcinoma (Cell Line: OVCAR3) [3]
Letrozole + Valrubicin DC7ZUQD Valrubicin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Letrozole + Valrubicin DCUXP29 Valrubicin Glioblastoma (Cell Line: SNB-75) [3]
Letrozole + Valrubicin DCC3Z6L Valrubicin Renal cell carcinoma (Cell Line: UO-31) [3]
Letrozole + Cisplatin DC5DFZD Cisplatin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Letrozole + Chlorambucil DCX83QM Chlorambucil Adenocarcinoma (Cell Line: NCIH23) [3]
Letrozole + Chlorambucil DC1PW12 Chlorambucil Adenocarcinoma (Cell Line: HCT-15) [3]
Letrozole + Chlorambucil DCF8BB1 Chlorambucil Amelanotic melanoma (Cell Line: M14) [3]
Letrozole + Chlorambucil DC3Z92P Chlorambucil Astrocytoma (Cell Line: U251) [3]
Letrozole + Chlorambucil DCTA8H9 Chlorambucil Glioma (Cell Line: SF-295) [3]
Letrozole + Chlorambucil DC4EQ1N Chlorambucil Lung adenocarcinoma (Cell Line: HOP-62) [3]
Letrozole + Chlorambucil DC6SW1F Chlorambucil Lung adenocarcinoma (Cell Line: EKVX) [3]
Letrozole + Chlorambucil DCJ8RR3 Chlorambucil Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Letrozole + Chlorambucil DCO2EUJ Chlorambucil Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Letrozole + Sorafenib DC7HBXR Sorafenib Adenocarcinoma (Cell Line: HCT116) [3]
Letrozole + Sorafenib DCUXQ8L Sorafenib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Letrozole + Sorafenib DC7Z1DB Sorafenib Lung adenocarcinoma (Cell Line: HOP-62) [3]
Letrozole + ER819762 DC2LTCL ER819762 Adenocarcinoma (Cell Line: OVCAR3) [3]
Letrozole + ER819762 DCQ412O ER819762 Adenocarcinoma (Cell Line: HCT-15) [3]
Letrozole + ER819762 DCD847N ER819762 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Letrozole + ER819762 DCIBAVO ER819762 Anaplastic large cell lymphoma (Cell Line: SR) [3]
Letrozole + ER819762 DCTYT5C ER819762 Glioma (Cell Line: SF-295) [3]
Letrozole + ER819762 DCBGHHH ER819762 Melanoma (Cell Line: UACC-257) [3]
Letrozole + Azacitidine DCZI38G Azacitidine Adenocarcinoma (Cell Line: OVCAR3) [3]
Letrozole + Azacitidine DC0AHZ4 Azacitidine Adenocarcinoma (Cell Line: NCIH23) [3]
Letrozole + Azacitidine DC6VX9J Azacitidine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Letrozole + Azacitidine DC5DSLM Azacitidine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Letrozole + Azacitidine DC4FCQ0 Azacitidine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Letrozole + Azacitidine DC487P2 Azacitidine Glioma (Cell Line: SF-539) [3]
Letrozole + Azacitidine DC859JD Azacitidine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Letrozole + Azacitidine DCXPA4F Azacitidine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Letrozole + Azacitidine DCG1EUV Azacitidine Malignant melanoma (Cell Line: LOX IMVI) [3]
Letrozole + Azacitidine DC6L1D2 Azacitidine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Letrozole + Azacitidine DC1V72L Azacitidine Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Letrozole + Azacitidine DC73VSJ Azacitidine Renal cell carcinoma (Cell Line: SN12C) [3]
Letrozole + Pomalidomide DCUG40I Pomalidomide Astrocytoma (Cell Line: U251) [3]
Letrozole + Pomalidomide DC5IY5U Pomalidomide Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Letrozole + Pomalidomide DC677ZX Pomalidomide Chronic myelogenous leukemia (Cell Line: K-562) [3]
Letrozole + Pomalidomide DC410IM Pomalidomide High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Letrozole + Pomalidomide DCVHIP6 Pomalidomide Lung adenocarcinoma (Cell Line: HOP-62) [3]
Letrozole + Pomalidomide DC0L05U Pomalidomide Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Letrozole + Vinflunine DCJZBEL Vinflunine Adenocarcinoma (Cell Line: OVCAR3) [3]
Letrozole + Vinflunine DCN8NO7 Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Letrozole + Mercaptopurine DCCJJFI Mercaptopurine Adenocarcinoma (Cell Line: HCC-2998) [3]
Letrozole + Mercaptopurine DCLPI78 Mercaptopurine Glioma (Cell Line: SF-268) [3]
Letrozole + Mercaptopurine DCQKOND Mercaptopurine Lung adenocarcinoma (Cell Line: HOP-62) [3]
Letrozole + Mercaptopurine DCKSS77 Mercaptopurine Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Letrozole + Mercaptopurine DCJH8G2 Mercaptopurine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Letrozole + Fludarabine DC6FCWW Fludarabine Adenocarcinoma (Cell Line: SW-620) [3]
Letrozole + Fludarabine DC3CBOU Fludarabine Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Letrozole + Fludarabine DCVR2UW Fludarabine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Letrozole + PMID28870136-Compound-43 DCPM8SG PMID28870136-Compound-43 Adenocarcinoma (Cell Line: DU-145) [3]
Letrozole + PMID28870136-Compound-43 DCC15A0 PMID28870136-Compound-43 Adenocarcinoma (Cell Line: HCT116) [3]
Letrozole + PMID28870136-Compound-43 DCCDZUX PMID28870136-Compound-43 Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Letrozole + PMID28870136-Compound-43 DCHGNEP PMID28870136-Compound-43 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Letrozole + FORMESTANE DCPB36T FORMESTANE Adenocarcinoma (Cell Line: OVCAR3) [3]
Letrozole + FORMESTANE DCA4Z35 FORMESTANE Chronic myelogenous leukemia (Cell Line: K-562) [3]
Letrozole + FORMESTANE DC8H2G6 FORMESTANE Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Letrozole + Aminolevulinic Acid Hydrochloride DCGZ49A Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: DU-145) [3]
Letrozole + Aminolevulinic Acid Hydrochloride DCB0Y5X Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: OVCAR3) [3]
Letrozole + Aminolevulinic Acid Hydrochloride DCDSZO9 Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: A549) [3]
Letrozole + Aminolevulinic Acid Hydrochloride DCFVQCX Aminolevulinic Acid Hydrochloride Astrocytoma (Cell Line: U251) [3]
Letrozole + Aminolevulinic Acid Hydrochloride DCMQOAO Aminolevulinic Acid Hydrochloride Glioma (Cell Line: SF-268) [3]
Letrozole + Aminolevulinic Acid Hydrochloride DCZZ385 Aminolevulinic Acid Hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Letrozole + Aminolevulinic Acid Hydrochloride DCL0X0Z Aminolevulinic Acid Hydrochloride Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Letrozole + Aminolevulinic Acid Hydrochloride DC4RWV5 Aminolevulinic Acid Hydrochloride Lung adenocarcinoma (Cell Line: HOP-62) [3]
Letrozole + Aminolevulinic Acid Hydrochloride DCDDPEY Aminolevulinic Acid Hydrochloride Malignant melanoma (Cell Line: LOX IMVI) [3]
Letrozole + Aminolevulinic Acid Hydrochloride DCTYF5J Aminolevulinic Acid Hydrochloride Melanoma (Cell Line: SK-MEL-2) [3]
Letrozole + Aminolevulinic Acid Hydrochloride DCWI76F Aminolevulinic Acid Hydrochloride Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Letrozole + Estramustine DC5TE97 Estramustine Adenocarcinoma (Cell Line: SW-620) [3]
Letrozole + Estramustine DCEPM0W Estramustine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Letrozole + Estramustine DCE96HM Estramustine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Letrozole + Estramustine DCJ79OL Estramustine Lung adenocarcinoma (Cell Line: EKVX) [3]
Letrozole + Digitoxin DCFPO5Z Digitoxin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Letrozole + Busulfan DCC7KQW Busulfan Adenocarcinoma (Cell Line: DU-145) [3]
Letrozole + Busulfan DC24Y5I Busulfan Adenocarcinoma (Cell Line: HCT-15) [3]
Letrozole + Busulfan DC24BHY Busulfan Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Letrozole + Busulfan DCTPM83 Busulfan Anaplastic large cell lymphoma (Cell Line: SR) [3]
Letrozole + Busulfan DCPBH9K Busulfan Astrocytoma (Cell Line: U251) [3]
Letrozole + Busulfan DCPHO3Y Busulfan Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Letrozole + Busulfan DCHDR52 Busulfan Glioblastoma (Cell Line: SNB-75) [3]
Letrozole + Busulfan DC3OQXC Busulfan Glioma (Cell Line: SF-268) [3]
Letrozole + Busulfan DCX9F86 Busulfan Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Letrozole + Busulfan DCCBWRL Busulfan Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Letrozole + Busulfan DCW8A0O Busulfan Malignant melanoma (Cell Line: LOX IMVI) [3]
Letrozole + Busulfan DCDGV8Q Busulfan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Letrozole + Dasatinib DC1RMIV Dasatinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Letrozole + Pentostatin DCGLA15 Pentostatin Colon adenocarcinoma (Cell Line: COLO 205) [4]
Letrozole + Dactinomycin DC2GXBS Dactinomycin Carcinoma (Cell Line: RXF 393) [4]
Letrozole + Dactinomycin DCMBNEQ Dactinomycin Carcinoma (Cell Line: MCF7) [4]
Letrozole + Dactinomycin DCW2KE0 Dactinomycin Colon carcinoma (Cell Line: KM12) [4]
Letrozole + DFN-15 DCZ3QWV DFN-15 Invasive ductal carcinoma (Cell Line: BT-549) [4]
Letrozole + DFN-15 DC9N9Y5 DFN-15 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Letrozole + Lapatinib DCB9N7U Lapatinib Colon carcinoma (Cell Line: KM12) [4]
Letrozole + Cyclophosphamide DCD0Y8N Cyclophosphamide Invasive ductal carcinoma (Cell Line: T-47D) [4]
Letrozole + Methotrexate DC7YPZF Methotrexate Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Letrozole + Methotrexate DCXMYNH Methotrexate Invasive ductal carcinoma (Cell Line: BT-549) [4]
Letrozole + Plicamycin DCDHS4F Plicamycin Colon carcinoma (Cell Line: KM12) [4]
Letrozole + Plicamycin DCWGPL8 Plicamycin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Letrozole + Triapine DCN9OGM Triapine Invasive ductal carcinoma (Cell Line: BT-549) [4]
Letrozole + Ifosfamide DCYH69N Ifosfamide Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Letrozole + Bendamustine hydrochloride DCFGD57 Bendamustine hydrochloride Carcinoma (Cell Line: RXF 393) [4]
Letrozole + Bendamustine hydrochloride DCSCGV8 Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Letrozole + SY-1425 DCF2GUB SY-1425 Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Letrozole + Altretamine DC42FR4 Altretamine Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Letrozole + Altretamine DCWW2I3 Altretamine Invasive ductal carcinoma (Cell Line: T-47D) [4]
Letrozole + TEM DCHSA7A TEM Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Letrozole + Idarubicin DC9BSG5 Idarubicin Colon adenocarcinoma (Cell Line: COLO 205) [4]
Letrozole + Imatinib DCJ01KK Imatinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Letrozole + Valrubicin DCMLH89 Valrubicin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Letrozole + Valrubicin DCDI3MI Valrubicin Colon carcinoma (Cell Line: KM12) [4]
Letrozole + Cisplatin DCTZBVT Cisplatin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Letrozole + Azacitidine DCVBH5F Azacitidine Colon carcinoma (Cell Line: KM12) [4]
Letrozole + Pomalidomide DCR7SQD Pomalidomide Carcinoma (Cell Line: RXF 393) [4]
Letrozole + Pomalidomide DC4RTES Pomalidomide Invasive ductal carcinoma (Cell Line: T-47D) [4]
Letrozole + Vinflunine DCXMSQ6 Vinflunine Colon carcinoma (Cell Line: KM12) [4]
Letrozole + Mepacrine DC5AWF5 Mepacrine Carcinoma (Cell Line: MCF7) [4]
Letrozole + PMID28870136-Compound-43 DCNO5GP PMID28870136-Compound-43 Carcinoma (Cell Line: RXF 393) [4]
Letrozole + PMID28870136-Compound-43 DCJGTL7 PMID28870136-Compound-43 Colon adenocarcinoma (Cell Line: COLO 205) [4]
Letrozole + PMID28870136-Compound-43 DC1Z0CZ PMID28870136-Compound-43 Colon carcinoma (Cell Line: KM12) [4]
Letrozole + FORMESTANE DCFLN1E FORMESTANE Carcinoma (Cell Line: RXF 393) [4]
Letrozole + Estramustine DC64H7E Estramustine Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Letrozole + Dasatinib DCP9NFL Dasatinib Colon adenocarcinoma (Cell Line: COLO 205) [4]
Mechlorethamine + Letrozole DCTRAXL Mechlorethamine Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Mechlorethamine + Letrozole DCH7WLL Mechlorethamine Adenocarcinoma (Cell Line: HCT116) [5]
Mechlorethamine + Letrozole DCT1ZPM Mechlorethamine Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Picoplatin + Letrozole DC6KRY1 Picoplatin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Picoplatin + Letrozole DC2K7ZN Picoplatin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Picoplatin + Letrozole DCJEUQ9 Picoplatin Prostate carcinoma (Cell Line: PC-3) [5]
Raloxifene + Letrozole DCFRLP5 Raloxifene Chronic myelogenous leukemia (Cell Line: K-562) [3]
Raloxifene + Letrozole DC0KEEB Raloxifene Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Raloxifene + Letrozole DCRVIM4 Raloxifene Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Raloxifene + Letrozole DCGVBQD Raloxifene Invasive ductal carcinoma (Cell Line: BT-549) [4]
Raloxifene + Letrozole DCK2R7M Raloxifene Invasive ductal carcinoma (Cell Line: T-47D) [4]
Raloxifene + Letrozole DC382EL Raloxifene Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Raloxifene + Letrozole DCEMHVB Raloxifene Adenocarcinoma (Cell Line: SW-620) [5]
Raloxifene + Letrozole DCBDMW4 Raloxifene Adenocarcinoma (Cell Line: HCC-2998) [5]
Raloxifene + Letrozole DCY3PYK Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Raloxifene + Letrozole DCR6OGU Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Raloxifene + Letrozole DCBQD3B Raloxifene Lung adenocarcinoma (Cell Line: EKVX) [5]
Raloxifene + Letrozole DC1PIW8 Raloxifene Malignant melanoma (Cell Line: UACC62) [5]
Raloxifene + Letrozole DC8EQUV Raloxifene Prostate carcinoma (Cell Line: PC-3) [5]
Ruxolitinib + Letrozole DC5KUCO Ruxolitinib Clear cell renal cell carcinoma (Cell Line: A498) [3]
Ruxolitinib + Letrozole DCP2B22 Ruxolitinib Glioma (Cell Line: SF-268) [3]
Ruxolitinib + Letrozole DCDX6HX Ruxolitinib Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Ruxolitinib + Letrozole DCJ0PIC Ruxolitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Ruxolitinib + Letrozole DC9SSUQ Ruxolitinib Carcinoma (Cell Line: MCF7) [4]
Ruxolitinib + Letrozole DCP7V90 Ruxolitinib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Ruxolitinib + Letrozole DC4IWIS Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Ruxolitinib + Letrozole DCAFCJQ Ruxolitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Ruxolitinib + Letrozole DCOBDZZ Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Ruxolitinib + Letrozole DC5BP62 Ruxolitinib Melanoma (Cell Line: SK-MEL-2) [5]
Ruxolitinib + Letrozole DC0F35M Ruxolitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Thioguanine + Letrozole DC0ABS5 Thioguanine Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Thioguanine + Letrozole DCOCZU8 Thioguanine Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Thioguanine + Letrozole DCOT3OH Thioguanine Adenocarcinoma (Cell Line: NCIH23) [5]
Thioguanine + Letrozole DCT9XYE Thioguanine Adenocarcinoma (Cell Line: SW-620) [5]
Thioguanine + Letrozole DCCL7S4 Thioguanine Adenocarcinoma (Cell Line: HCT-15) [5]
Thioguanine + Letrozole DC8R2SI Thioguanine Adenocarcinoma (Cell Line: HCT116) [5]
Thioguanine + Letrozole DC1VLTX Thioguanine Prostate carcinoma (Cell Line: PC-3) [5]
Topotecan + Letrozole DC4FWJL Topotecan Carcinoma (Cell Line: MCF7) [4]
Topotecan + Letrozole DCK252G Topotecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Topotecan + Letrozole DCMPKGZ Topotecan Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Topotecan + Letrozole DCGL4CI Topotecan Astrocytoma (Cell Line: SNB-19) [5]
Topotecan + Letrozole DCOUP7U Topotecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Topotecan + Letrozole DCZPR1R Topotecan Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Topotecan + Letrozole DCZEQHB Topotecan Melanoma (Cell Line: UACC-257) [5]
Topotecan + Letrozole DCNLQVD Topotecan Melanoma (Cell Line: MALME-3M) [5]
Topotecan + Letrozole DC3SIE5 Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Topotecan + Letrozole DCVDM0H Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Topotecan + Letrozole DCEX7IM Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Topotecan + Letrozole DCHXD9D Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Topotecan + Letrozole DCXYS49 Topotecan Prostate carcinoma (Cell Line: PC-3) [5]
Trifluridine + Letrozole DC3B0OR Trifluridine Adenocarcinoma (Cell Line: DU-145) [5]
Trifluridine + Letrozole DCOABR4 Trifluridine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vandetanib + Letrozole DCG2336 Vandetanib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vandetanib + Letrozole DCAT2GY Vandetanib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vandetanib + Letrozole DC6OXI1 Vandetanib Amelanotic melanoma (Cell Line: M14) [5]
Vandetanib + Letrozole DC1AQT8 Vandetanib Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vandetanib + Letrozole DCX4X0G Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vandetanib + Letrozole DCAAN46 Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vandetanib + Letrozole DC9GV90 Vandetanib Glioma (Cell Line: SF-268) [5]
Vandetanib + Letrozole DCF5JU8 Vandetanib Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vandetanib + Letrozole DCA0G8O Vandetanib Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vemurafenib + Letrozole DC33Y34 Vemurafenib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vemurafenib + Letrozole DCWXLV5 Vemurafenib Carcinoma (Cell Line: MCF7) [4]
Vemurafenib + Letrozole DCB5K45 Vemurafenib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vemurafenib + Letrozole DCKBSC9 Vemurafenib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vemurafenib + Letrozole DC6ZOQW Vemurafenib Adenocarcinoma (Cell Line: HCT-15) [5]
Vemurafenib + Letrozole DC9F4QF Vemurafenib Adenocarcinoma (Cell Line: HCT116) [5]
Vemurafenib + Letrozole DC0X2RZ Vemurafenib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vemurafenib + Letrozole DC75W88 Vemurafenib Astrocytoma (Cell Line: SNB-19) [5]
Vemurafenib + Letrozole DCNA32Y Vemurafenib Glioma (Cell Line: SF-268) [5]
Vemurafenib + Letrozole DCIVTHE Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vemurafenib + Letrozole DCVF3ZJ Vemurafenib Lung adenocarcinoma (Cell Line: EKVX) [5]
Vemurafenib + Letrozole DCX3Y5O Vemurafenib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vemurafenib + Letrozole DCJ5S5U Vemurafenib Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vemurafenib + Letrozole DCV2FAF Vemurafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vemurafenib + Letrozole DCM40Y4 Vemurafenib Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vemurafenib + Letrozole DC9Z977 Vemurafenib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vemurafenib + Letrozole DC48YAO Vemurafenib Prostate carcinoma (Cell Line: PC-3) [5]
Vemurafenib + Letrozole DC7MLZO Vemurafenib Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Letrozole DCBRM4Z Vismodegib Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Letrozole DCDJ3U4 Vismodegib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Letrozole DCNDIJ8 Vismodegib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Letrozole DCW4KXY Vismodegib Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + Letrozole DCPR1JI Vismodegib Adenocarcinoma (Cell Line: SW-620) [5]
Vismodegib + Letrozole DCBNUML Vismodegib Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Letrozole DCCNPM5 Vismodegib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Letrozole DCQKII7 Vismodegib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Letrozole DCB1BTO Vismodegib Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Letrozole DCJSSM6 Vismodegib Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vismodegib + Letrozole DCAWV0D Vismodegib Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Letrozole DCOQI9I Vismodegib Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Letrozole DCOCUPH Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Letrozole DCTCPTX Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Letrozole DC5PXRA Vismodegib Glioma (Cell Line: SF-268) [5]
Vismodegib + Letrozole DCTTCWH Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vismodegib + Letrozole DC9H3HA Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Letrozole DC7HWT4 Vismodegib Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Letrozole DCLIOJX Vismodegib Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Letrozole DC95AU0 Vismodegib Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Letrozole DC62KIR Vismodegib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Letrozole DC9JE2Y Vismodegib Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Letrozole DC4V1OJ Vismodegib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Letrozole DCGZNA5 Vismodegib Renal cell carcinoma (Cell Line: SN12C) [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 431 DrugCom(s)
68 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Alpelisib + Letrozole DCAOYYN Alpelisib Breast Cancer [6]
Alpelisib + Letrozole DC3K9YO Alpelisib Metastatic or Locally-advanced Unresectable Breast Cancer [7]
Buparlisib + Letrozole DCX0RQ4 Buparlisib Metastatic Breast Cancer [8]
Buparlisib + Letrozole DC35L9F Buparlisib Advanced or Metastatic Breast Cancer [9]
Cyclophosphamide + Letrozole DCESL59 Cyclophosphamide Breast Cancer [10]
Everolimus + Letrozole DC1XTHT Everolimus Postmenopausal Women [11]
Everolimus + Letrozole DCBYD0M Everolimus Advanced Malignant Solid Neoplasm [12]
Exemestane + Letrozole DC565RC Exemestane Male Breast Cancer [13]
Exemestane + Letrozole DCL9I4L Exemestane Breast Cancer [14]
Fulvestrant + Letrozole DCLJLDI Fulvestrant Breast Cancer [15]
GDC0941 + Letrozole DCQ50K6 GDC0941 Breast Cancer [16]
Lapatinib + Letrozole DCHGDDP Lapatinib Neoplasms, Breast [17]
Lapatinib + Letrozole DCKK4B7 Lapatinib Breast Neoplasms [18]
Letrozole + Zoledronate DCIMZA7 Zoledronate Breast Cancer [19]
Letrozole + Clomifene DC5SM9V Clomifene Infertility [20]
Letrozole + Zoledronate DC61NWM Zoledronate Breast Neoplasms [21]
Letrozole + Anastrozole DC9ZJJD Anastrozole Breast Cancer [22]
Letrozole + BMS-690514 DCBE6FO BMS-690514 Breast Cancer [23]
Letrozole + Xl147 DCEWMG0 Xl147 Breast Cancer [24]
Letrozole + GDC-0032 DCLZ8LP GDC-0032 Solid Cancers [25]
Letrozole + Bosutinib DCROX04 Bosutinib Breast Cancer [26]
Letrozole + Triptorelin DCU5C0O Triptorelin Breast Cancer [19]
Letrozole + Zoledronate DCVIW9B Zoledronate Breast Cancer [27]
Letrozole + Dasatinib DCYLKRD Dasatinib Metastatic Breast Cancer [28]
Letrozole + Vinorelbine DC1JH47 Vinorelbine Breast Cancer [29]
Letrozole + Nintedanib DC896SH Nintedanib Breast Cancer [30]
Letrozole + GDC-0068 DCCTZ36 GDC-0068 Breast Cancer [31]
Letrozole + Temozolomide DCF09QX Temozolomide Brain Tumor [32]
Letrozole + Sapanisertib DCHC556 Sapanisertib Breast Cancer [33]
Letrozole + LEE011 DCS02AM LEE011 Breast Cancer [6]
LY2835219 + Letrozole DCBRVQY LY2835219 Breast Neoplasms [34]
Mifepristone + Letrozole DCR8JVT Mifepristone Complete Abortion [35]
Olaparib + Letrozole DC8E9XL Olaparib Solid Tumours [36]
Palbociclib + Letrozole DCKLEF1 Palbociclib Neoplasms [37]
Palbociclib + Letrozole DCKM9VL Palbociclib Breast Neoplasms [38]
Palbociclib + Letrozole DCMXE98 Palbociclib Anatomic Stage I Breast Cancer AJCC v8 [39]
Panobinostat + Letrozole DCAWDFL Panobinostat Breast Cancer [40]
RTB101 + Letrozole DC9YJI0 RTB101 Metastatic Breast Cancer [8]
Simvastatin + Letrozole DC8LAUF Simvastatin Anatomic Stage I Breast Cancer AJCC v8 [41]
Degarelix + Letrozole DCBT079 Degarelix Breast Cancer Invasive Nos [42]
Everolimus + Letrozole DC8R6NG Everolimus Recurrent Endometrial Carcinoma [43]
Exemestane + Letrozole DCUQK86 Exemestane Estrogen Receptor Negative [44]
Exemestane + Letrozole DCZHHUA Exemestane Breast Cancer [45]
Goserelin + Letrozole DCCJUSF Goserelin Estrogen Receptor-positive Breast Cancer [46]
Goserelin + Letrozole DCLZPT8 Goserelin Invasive Lobular Breast Carcinoma [47]
Goserelin + Letrozole DCN5B53 Goserelin Metastatic Breast Cancer [48]
Letrozole + Anastrozole DCF5OEQ Anastrozole Breast Cancer [49]
Letrozole + Misoprostol DC5VRXS Misoprostol Miscarriage [50]
Letrozole + LEE011 DC6QCIJ LEE011 Early Breast Cancer [51]
Letrozole + Tamoxifen DC9ZSUV Tamoxifen Breast Cancer [52]
Letrozole + Bicalutamide DCAZI7U Bicalutamide Breast Cancer [53]
Letrozole + Anastrozole DCDFSM5 Anastrozole Anatomic Stage I Breast Cancer AJCC v8 [54]
Letrozole + Triptorelin DCM2F0J Triptorelin Breast Cancer Invasive Nos [42]
Letrozole + Afatinib DCRF0IM Afatinib Breast Neoplasms [55]
Leuprolide + Letrozole DCB32SG Leuprolide Breast Cancer [56]
Leuprolide + Letrozole DC4JITU Leuprolide Endometrial Neoplasms [57]
Leuprolide + Letrozole DC4WU4F Leuprolide Metastatic Breast Cancer [58]
Leuprolide + Letrozole DCJE91Y Leuprolide Breast Cancer [59]
LY2835219 + Letrozole DC3V2G3 LY2835219 Recurrent Endometrial Carcinoma [60]
LY2835219 + Letrozole DCPBCJQ LY2835219 Endometrial Cancer [61]
Exemestane + Letrozole DCSL7NG Exemestane Breast Cancer [62]
Exemestane + Letrozole DC93Z3D Exemestane Breast Cancer [63]
Goserelin + Letrozole DC0IC7N Goserelin Advanced Metastatic Breast Cancer [64]
Letrozole + Anastrozole DCU90CT Anastrozole Breast Cancer [65]
Letrozole + Capecitabine DC3E3U8 Capecitabine Breast Cancer [66]
LY2835219 + Letrozole DCCPSYD LY2835219 Breast Cancer [67]
Letrozole + Flutamide DCC2CUQ Flutamide Congenital Adrenal Hyperplasia (CAH) [68]
Letrozole + Flutamide DCYZZS0 Flutamide Congenital Adrenal Hyperplasia (CAH) [68]
------------------------------------------------------------------------------------
⏷ Show the Full List of 68 DrugCom(s)

References

1 Letrozole FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5209).
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
6 ClinicalTrials.gov (NCT01872260) Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
7 ClinicalTrials.gov (NCT01870505) BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
8 ClinicalTrials.gov (NCT01248494) PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
9 ClinicalTrials.gov (NCT02154776) Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.
10 ClinicalTrials.gov (NCT04895761) Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
11 ClinicalTrials.gov (NCT01231659) Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
12 ClinicalTrials.gov (NCT02152943) Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
13 ClinicalTrials.gov (NCT01153672) Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
14 ClinicalTrials.gov (NCT00719966) Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer
15 ClinicalTrials.gov (NCT00545077) Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
16 ClinicalTrials.gov (NCT00960960) A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
17 ClinicalTrials.gov (NCT00422903) Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
18 ClinicalTrials.gov (NCT00073528) Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
19 ClinicalTrials.gov (NCT00412022) HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
20 ClinicalTrials.gov (NCT02294773) Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit
21 ClinicalTrials.gov (NCT00050011) Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
22 ClinicalTrials.gov (NCT00681928) Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy
23 ClinicalTrials.gov (NCT01068704) Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
24 ClinicalTrials.gov (NCT01082068) Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
25 ClinicalTrials.gov (NCT01296555) A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
26 ClinicalTrials.gov (NCT00880009) Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer
27 ClinicalTrials.gov (NCT00107263) Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
28 ClinicalTrials.gov (NCT00696072) Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
29 ClinicalTrials.gov (NCT02802748) Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)
30 ClinicalTrials.gov (NCT02619162) Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics
31 ClinicalTrials.gov (NCT03959891) AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
32 ClinicalTrials.gov (NCT03122197) Study of Letrozole in Recurrent Gliomas
33 ClinicalTrials.gov (NCT02619669) Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
34 ClinicalTrials.gov (NCT02057133) A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
35 ClinicalTrials.gov (NCT01475318) Study on Combined Use of Letrozole, Mifepristone and Misoprostol in Termination of Pregnancy
36 ClinicalTrials.gov (NCT02093351) To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
37 ClinicalTrials.gov (NCT01684215) A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
38 ClinicalTrials.gov (NCT01740427) A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
39 ClinicalTrials.gov (NCT03774472) Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
40 ClinicalTrials.gov (NCT01105312) Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
41 ClinicalTrials.gov (NCT05464810) Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
42 ClinicalTrials.gov (NCT02005887) TRial on the Endocrine Activity of Neoadjuvant Degarelix
43 ClinicalTrials.gov (NCT03008408) A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
44 ClinicalTrials.gov (NCT02648477) Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
45 ClinicalTrials.gov (NCT00573755) Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
46 ClinicalTrials.gov (NCT01368263) Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
47 ClinicalTrials.gov (NCT04551495) Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)
48 ClinicalTrials.gov (NCT02313051) Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
49 ClinicalTrials.gov (NCT02585388) Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.
50 ClinicalTrials.gov (NCT03628625) Letrozole Pretreatment With Misoprostol fInduction of Abortion In First-Trimester Missed Miscarriage
51 ClinicalTrials.gov (NCT01919229) A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
52 ClinicalTrials.gov (NCT02764541) Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
53 ClinicalTrials.gov (NCT02910050) Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer
54 ClinicalTrials.gov (NCT04294225) Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
55 ClinicalTrials.gov (NCT02115048) Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
56 ClinicalTrials.gov (NCT00903162) Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
57 ClinicalTrials.gov (NCT05316935) GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
58 ClinicalTrials.gov (NCT02344550) Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer
59 ClinicalTrials.gov (NCT03900637) PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate
60 ClinicalTrials.gov (NCT04469764) Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
61 ClinicalTrials.gov (NCT03675893) Abemaciclib + Letrozole +/- Metformin in Recurrent or Persistent Endometrial Cancer
62 ClinicalTrials.gov (NCT02995772) Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients
63 ClinicalTrials.gov (NCT00893061) Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer
64 ClinicalTrials.gov (NCT03096847) Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
65 ClinicalTrials.gov (NCT02730091) A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
66 ClinicalTrials.gov (NCT02767661) Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer
67 ClinicalTrials.gov (NCT02246621) A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
68 ClinicalTrials.gov (NCT00001521) Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia